Ultrasound and chemotherapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new treatment that uses ultrasound to help chemotherapy reach liver tumors in people with advanced pancreatic cancer. It may help shrink tumors and improve how well the chemotherapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with pancreatic cancer that has spread to your liver.
- You have at least two liver tumors, and at least one is between 1 and 5 cm wide and not too deep under the skin.
- You have already tried a standard chemotherapy called gemcitabine, and it did not work well enough.
- You are healthy enough to receive the study treatment, with good blood counts, liver and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding focused ultrasound (a treatment that uses sound waves to target the tumor) to standard chemotherapy can help shrink or control pancreatic cancer in people whose cancer is borderline resectable or locally advanced. It aims to see if this combination is more effective than chemotherapy alone.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
Hear when a new Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.